BiotechTube
ABL

ABL

Lyon, France· Est.
abl-biomanufacturing.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

ABL is a specialized CDMO focused on advanced therapies, operating from Lyon, France since 2006. It offers end-to-end contract services for biologics, cell therapies, and viral vectors, positioning itself in the high-growth cell and gene therapy manufacturing sector. As a private company, it caters to the outsourced manufacturing needs of biopharma innovators, though specific financial details and leadership are not publicly disclosed on its currently unavailable website. Its value proposition lies in providing the technical expertise and GMP facilities required for complex therapeutic modalities.

BiologicsCell TherapyAntibodies

Technology Platform

Contract development and manufacturing platform for biologics, cell therapies, and viral vectors, encompassing process development, GMP production, and analytical services.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The global surge in cell and gene therapy development creates massive demand for specialized CDMO capacity.
ABL's European base allows it to serve a strong regional biotech hub and global clients seeking a strategic partner under EMA standards.
Long-term commercial supply agreements for successful therapies offer recurring, high-value revenue streams.

Risk Factors

Operational risks are high due to the technical complexity of manufacturing cell therapies and viral vectors, where process failures can damage client relationships.
Revenue is susceptible to client concentration and clinical trial setbacks of partner programs.
Intense competition from larger, global CDMOs could pressure pricing and market share.

Competitive Landscape

ABL competes in a fragmented but consolidating CDMO market. It faces competition from large, diversified CDMOs (e.g., Lonza, Catalent, Thermo Fisher/Patheon), pure-play viral vector specialists (e.g., Oxford Biomedica, Genezen), and other regional European CDMOs. Its differentiation hinges on technical expertise in advanced therapies, quality, customer service, and flexibility as a mid-sized player.

More companies in Diagnostics & Precision Medicine →More companies in France →